Celsion Announces AMEX Listing Compliance.

COLUMBIA, Md. -- CELSION CORPORATION (AMEX:CLN) announced today that it has received confirmation from the American Stock Exchange (AMEX) that the Company has resolved the continued listing deficiencies cited in a letter from the AMEX dated June 14, 2006. As previously disclosed, the Company submitted a plan, which was accepted by the Amex on August 31, 2006, to achieve compliance with the continued listing standards of the AMEX by December 14, 2007.

The Company met the continued listing standards in the quarter ended June 30, 2007. However, according to AMEX rules, the Company must demonstrate continued compliance for two consecutive quarters. If the Company fails to demonstrate compliance for two consecutive quarters by December 14, 2007, delisting procedures could be resumed.

Mr. Michael Tardugno, Celsion's President and Chief Executive Officer, commented, "We are pleased that this issue is currently behind us and are confident that we will remain in compliance. Removal of compliance concerns further enables us to sharpen our focus on completion of our clinical studies and obtaining approval for ThermoDox([R])."

About Celsion: Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and North Shore Long Island Jewish Health System.

Celsion has also developed a microwave based system, the Prolieve Thermodilatation[R] system, for the treatment of benign prostatic hyperplasia which is marketed in the United States under an exclusive distribution agreement with Boston Scientific Corporation. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.